Despite the availability of vaccines and antimicrobial agents, enteric fever causes high morbidity and mortality and accounts for 11.9 million typhoid fever illnesses and 129,000 deaths in developing countries[@ref1][@ref2]. The treatment continues to pose major therapeutic challenge due to the emergence of antimicrobial resistance in *Salmonella enterica* serovars Typhi and Paratyphi A, two major pathogens causing enteric fever[@ref3]. For multiple drug resistant strains, which were resistant to first-line drugs *i.e.* chloramphenicol, amoxicillin and co-trimoxazole, ciprofloxacin became the first line of treatment in enteric fever[@ref4]. However, soon after, the reports of clinical failure to ciprofloxacin therapy started to appear even when the laboratory reports interpreted the strain as susceptible using the Clinical and Laboratory Standard Institute (CLSI) guidelines at that time[@ref5][@ref6]. The guidelines being used at that time had same interpretative criteria for all members of *Enterobacteriaceae*. It was reported in a few cases that despite adequate ciprofloxacin treatment the infection relapsed and the subsequent culture during relapse had a higher minimum inhibitory concentration (MIC) to ciprofloxacin, though still sensitive as per the CLSI criteria. Nalidixic acid, the first-generation quinolone correlated with clinical failure to ciprofloxacin[@ref7] and was recommended as a surrogate marker for extraintestinal salmonellae by CLSI in 2009[@ref8]. Later as more data were available, CLSI revised ciprofloxacin breakpoints in 2012 for typhoidal salmonellae[@ref9] and subsequently added other quinolones -- ofloxacin and levofloxacin in 2013[@ref10]. In 2015, pefloxacin was added as a surrogate marker for fluoroquinolones susceptibility[@ref11]. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has recommended the use of pefloxacin disk diffusion as a surrogate marker to determine the susceptibility for ciprofloxacin but does not have a recommendation for ofloxacin and levofloxacin[@ref12].

Quinolones act on the DNA gyrase and topoisomerase enzymes, inhibit replication and transcription activities and cause fragmentation of DNA[@ref13]. The mechanism of resistance to this class of antibiotics is most commonly associated with the mutations in quinolone resistance determining region (QRDR) of target genes *gyrA*, *gyrB*, *parC* and *parE*[@ref14]. The isolates with a single mutation in any of the target enzyme show reduced susceptibility to fluoroquinolones, and further accumulation of mutations results in double or triple mutant isolates which have higher MIC to quinolones due to the cumulative effect of mutations[@ref15]. Other mechanisms of resistance are the presence of plasmid-mediated *qnr* genes and overexpression of efflux pumps but are rarely present in typhoidal salmonellae[@ref16].

These complex and multiple mechanisms impart resistance and their interplay may be the reason responsible for discordance between the clinical and laboratory results. A single mechanism cannot be specifically attributed to increase in MIC and clinical failure. The advantage of fluoroquinolones is their bactericidal activity, better tolerance and ease of administration. As guidelines for ciprofloxacin for susceptibility in S. Typhi and S. Paratyphi A are being revised frequently and levofloxacin and ofloxacin recommendations are available as MIC breakpoints only, it is ideal to have a surrogate marker which can be used to determine the resistance on the basis of simple disk diffusion method that can be done in a routine clinical microbiology laboratory in low resource setting also.

The present study was carried out to evaluate the present CLSI guidelines[@ref11] in clinical isolates of S. Typhi and S. Paratyphi A from India to determine the use of pefloxacin as a surrogate marker in these isolates.

Material & Methods {#sec1-1}
==================

A total number of 412 S. Typhi and S. Paratyphi A strains isolated from the enteric fever patients were included in the study. Strains were collected from two centres; 352 strains (303 S. Typhi and 49 S. Paratyphi A) were obtained from All India Institute of Medical Sciences (AIIMS), New Delhi. This included all the strains isolated during 1993-2015 available from archived collection of cryopreserved strains in the department of Microbiology, AIIMS. Sixty strains isolated from Christian Medical College, Vellore, isolated during 2010-2013 were also included. The study was approved by the Institutional Ethical Committees of the participating institutes.

All strains were obtained from blood cultures from the patients suspected to have enteric fever and were preserved as glycerol stocks at -70°C. The stocks were revived and reconfirmed by standard biochemical methods comprising motility, citrate utilization, glucose fermentation, H~2~S production, dulcitol fermentation and decarboxylase reaction[@ref17]. The identification was further confirmed by slide agglutination test with specific antisera (Statens Serum Institute, Copenhagen, Denmark).

 {#sec2-1}

### Antimicrobial susceptibility testing {#sec3-1}

Antimicrobial susceptibility testing was done using Kirby-Bauer disk diffusion method[@ref18] for nalidixic acid (30 μg), ciprofloxacin (5 μg), levofloxacin (5 μg), ofloxacin (5 μg) and pefloxacin (5 μg) (Oxoid Ltd., United Kingdom)[@ref11]. MIC was determined for ciprofloxacin, ofloxacin and levofloxacin with E-test as per manufacturer\'s guidelines (BioMerieux, France). Susceptibility interpretation was done using CLSI guidelines[@ref11]. For result interpretation, intermediate and resistant strains were considered together as resistant. *Escherichia coli* ATCC 25922 was used as a quality control strain for disk diffusion and MIC determination.

### Sequencing of topoisomerase genes {#sec3-2}

QRDR of *gyrA*, *gyrB*, *parC* and *parE* genes were sequenced using previous primers as standardized in our laboratory and determined the relation between mutations to these genes and pefloxacin zone diameters[@ref14][@ref15].

### Statistical analysis {#sec3-3}

Antimicrobial susceptibility data were analyzed in STATA (Version 11.1, Stata Corp., College Station, Texas, USA). Non-parametric test for trend was performed to determine the temporal patterns of MIC to ciprofloxacin, ofloxacin and levofloxacin. Correlation analysis was done to find out the relationship between MIC trends of ciprofloxacin, levofloxacin and ofloxacin. Correlation coefficients of zone diameter for pefloxacin, ciprofloxacin, ofloxacin, levofloxacin and nalidixic acid were also determined.

Sensitivity, specificity and positive predictive value were determined for the use of pefloxacin disk diffusion as a surrogate marker for susceptibility to ciprofloxacin, ofloxacin and levofloxacin using their respective MICs as gold standard and pefloxacin disk diffusion result was used as test.

Results {#sec1-2}
=======

Of the 412 isolates, only 34 (8.25%) were susceptible to ciprofloxacin. Ciprofloxacin susceptibility percentage was also compared between CLSI 2015 and CLSI 2011 *i.e.* before the revision of breakpoints. As per the earlier interpretation criteria 329 (80.03%) isolates were susceptible to ciprofloxacin, but with revised criteria, only 34 (8.25%) remained susceptible while 309 (75%) showed decreased susceptibility and 69 (16.75%) were resistant. For ofloxacin, 33 (8%) isolates were susceptible, 309 (75%) were intermediate and 70 (16.99%) were resistant. Similarly for levofloxacin, susceptible, intermediate and resistant isolates were 33 (8%), 307 (74.5%) and 72 (17.47%), respectively. MIC~50~ and MIC~90~ values were found to be 0.38 and 8 μg/ml for ciprofloxacin, 1 and 24 μg/ml for ofloxacin and 1.5 and 32 μg/ml for levofloxacin, respectively.

MIC values of ciprofloxacin, ofloxacin and levofloxacin showed a definite increase over time which was significant (*P* \<0.001, *P* \<0.003 and *P* \<0.021, respectively). There was a positive correlation between MIC to ciprofloxacin and ofloxacin having correlation coefficient 0.917 (*P* \<0.001), and also between ciprofloxacin and levofloxacin and between levofloxacin and ofloxacin ([Table I](#T1){ref-type="table"}). Correlation coefficients of zone diameter for ciprofloxacin, ofloxacin, levofloxacin, pefloxacin and nalidixic acid are given in [Table II](#T2){ref-type="table"}. Scatter plot analysis was done to find out corresponding disk diffusion zones of ciprofloxacin and pefloxacin. The breakpoints for susceptible zones of inhibition for pefloxacin and ciprofloxacin corresponded to each other ([Fig. 1](#F1){ref-type="fig"}).

###### 

Pearson correlation matrix showing correlation coefficient (r) for minimum inhibitory concentration (MIC) of ciprofloxacin, ofloxacin and levofloxacin
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###### 

Pearson correlation matrix showing correlation coefficient (r) for zones of inhibition for ciprofloxacin, ofloxacin, levofloxacin, pefloxacin and nalidixic acid
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![Scatter plot analysis to find out corresponding disk diffusion zones of pefloxacin and ciprofloxacin. ZOI, zone of inhibition.](IJMR-145-687-g003){#F1}

Ciprofloxacin susceptible isolates showed a zone of inhibition from 25 to 32 mm using 5 μg pefloxacin disks. However, for pefloxacin susceptible isolates, MIC of ciprofloxacin ranged from 0.002 to 0.38 μg/ml and for pefloxacin resistant isolates MIC range was between 0.125 to 32 μg/ml ([Fig. 2](#F2){ref-type="fig"}).

![Frequency histogram showing segregated minimum inhibitory concentration (MIC) distribution of ciprofloxacin for pefloxacin susceptible and resistant *Salmonella* strains. Blue bar represents pefloxacin susceptible strains which have ciprofloxacin MIC range from 0.002 to 0.38 μg/ml while black bars represent pefloxacin resistant strains having ciprofloxacin MIC range between 0.125 to 32 μg/ml.](IJMR-145-687-g004){#F2}

Pefloxacin zone diameters and fluoroquinolones MIC results were compared to evaluate the predictive efficacy of pefloxacin as a surrogate marker for fluoroquinolones susceptibility. Of the total 412 isolates tested for pefloxacin susceptibility, 36 were sensitive to pefloxacin, and 376 were resistant. All pefloxacin resistant isolates were resistant to ciprofloxacin, ofloxacin and levofloxacin. Among 36 pefloxacin susceptible isolates, 34 were susceptible to ciprofloxacin, and two were intermediate, while 33 were susceptible to ofloxacin and levofloxacin and three were intermediate to these drugs.

The sensitivity, specificity and positive predictive values of pefloxacin as a surrogate marker using ciprofloxacin MIC as a gold standard were 100, 99.5 and 94.4 per cent, respectively. Similarly, the sensitivity, specificity and positive predictive values of pefloxacin as a surrogate marker using ofloxacin and levofloxacin MIC were 100, 99.2 and 91.7 per cent, respectively.

 {#sec2-2}

### Mechanisms of resistance {#sec3-4}

Sequence analysis of *gyrA*, *gyrB*, *parC* and *parE* revealed the presence of mutations in *gyrA* and *parC* genes, but no mutation was detected in *gyrB* or *parE* genes. MIC and zone diameter range of mutants and wild type isolates is given in [Table III](#T3){ref-type="table"}. All isolates with pefloxacin zone of inhibitions ≥24 mm were wild type *i.e.* did not possess any mutation in QRDR of DNA gyrase or topoisomerase genes.

###### 

Mutations in quinolone resistance determining region (QRDR) of *gyrA* and *parC* genes and corresponding MIC value range with pefloxacin zones of inhibition
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When compared the susceptibility percentage of two serovars it was observed that fluoroquinolones resistance was significantly higher in S. Paratyphi A. All S. Paratyphi A isolates were in resistance or intermediate category *i.e.* fluoroquinolone susceptibility in S. Paratyphi A serovar was 0 per cent as per CLSI 2015[@ref11].

Discussion {#sec1-3}
==========

Emerging resistance to antityphoidal drugs has been regularly reported from India[@ref19]. Though there has been a decrease in the prevalence of chloramphenicol resistant strains, probably due to the decreased use of chloramphenicol, but an increase in resistance to ciprofloxacin has also been observed from India[@ref20][@ref21]. Following the ciprofloxacin resistance, ceftriaxone became the drug of choice to treat enteric fever[@ref22][@ref23] but the reports on clinical failure to ceftriaxone started emerging from Asian region[@ref24].

Fluoroquinolones have good oral absorption, are bactericidal and are well tolerated. CLSI published evidence-based revision of ciprofloxacin MIC and disk diffusion interpretative criteria in 2012 where susceptibility breakpoints for MIC value has been lowered from ≤1 to ≤0.06 μg/ml, and zone diameter has been increased from ≥21 to ≥31 mm[@ref9]. Studies have shown that the change in CLSI recommendation for ciprofloxacin breakpoints has a significant impact on whether an isolate is classified as susceptible, intermediate or resistant[@ref25][@ref26]. Subsequently, in 2013, ofloxacin and levofloxacin MIC interpretative criteria were included as ≤0.12 μg/ml for susceptible isolates[@ref10], followed by the recommendation of the use of pefloxacin as a surrogate marker for fluoroquinolones susceptibility. Pefloxacin showed a sensitivity and specificity of 100 and 99.5 per cent respectively, with a positive predictive value of 94.4 per cent for ciprofloxacin susceptibility. All pefloxacin susceptible isolates were also susceptible to ciprofloxacin except two isolates having intermediate MIC to ciprofloxacin which were susceptible according to pefloxacin disk diffusion test. These variations need to be studied in a larger number of strains across the world.

EUCAST has also recommended the use of pefloxacin as a marker for ciprofloxacin susceptibility[@ref12], but has no recommendation for ofloxacin and levofloxacin susceptibility. For ciprofloxacin, there are only susceptible and resistant categories which are a better method of reporting according to EUCAST as it avoids the confusion in the clinical decision-making with the intermediate category. In the present study, all intermediate strains fell into resistant category according to surrogate marker interpretation.

It has been shown that pefloxacin disk diffusion provides a better separation for ciprofloxacin susceptibility than any other disk diffusion, even better than ciprofloxacin itself[@ref27][@ref28]. In addition, levofloxacin and ofloxacin have only MIC breakpoints and do not have disk diffusion criteria, which makes pefloxacin testing by disk diffusion a convenient method in resource poor settings where MIC determination is not possible[@ref29][@ref30]. A linear increase was observed in MIC to fluoroquinolones with time. The resistance percentage was higher in S. Paratyphi A than S. Typhi. Based on the molecular mechanism of resistance comparing pefloxacin susceptibility with mutations in the QRDR region of DNA gyrase, it was possible to segregate sensitive wild type from resistant mutant.

A word of caution is that while reporting the susceptibility results for fluoroquinolones in a culture positive enteric fever, pefloxacin should not be reported as it is a surrogate marker only and is not used in clinical practice.

The main limitation of the study was that the strains studied were from hospitals representing two regions of India only. There is a need to generate a larger community-based data to determine the concordance between the interpretation of surrogate marker and clinical outcomes.
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